159 related articles for article (PubMed ID: 27258067)
1. Expression of Cell Competition Markers at the Interface between p53 Signature and Normal Epithelium in the Human Fallopian Tube.
Kito M; Maeda D; Kudo-Asabe Y; Sato N; Shih IeM; Wang TL; Tanaka M; Terada Y; Goto A
PLoS One; 2016; 11(6):e0156069. PubMed ID: 27258067
[TBL] [Abstract][Full Text] [Related]
2. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
Wen J; Shi JL; Shen DH; Chen YX; Song QJ
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
[TBL] [Abstract][Full Text] [Related]
3. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
4. Serous tubal in situ carcinoma (STIC) in primary peritoneal serous carcinomas.
Horn LC; Kafkova S; Leonhardt K; Kellner C; Einenkel J
Int J Gynecol Pathol; 2013 Jul; 32(4):339-44. PubMed ID: 23722505
[TBL] [Abstract][Full Text] [Related]
5. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical Expression Status of p53, CD44v9, and Ki-67 in a Series of Fallopian Tube Lesions of High-grade Serous Carcinoma.
Sugimoto S; Uchiyama T; Kawahara N; Ohbayashi C; Kobayashi H
Int J Gynecol Pathol; 2021 Sep; 40(5):419-426. PubMed ID: 34397764
[TBL] [Abstract][Full Text] [Related]
7. Secretory cell outgrowths, p53 signatures, and serous tubal intraepithelial carcinoma in the fallopian tubes of patients with sporadic pelvic serous carcinoma.
Mittal N; Srinivasan R; Gupta N; Rajwanshi A; Nijhawan R; Gautam U; Sood S; Dhaliwal L
Indian J Pathol Microbiol; 2016; 59(4):481-488. PubMed ID: 27721278
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Primary Cilia in Normal Fallopian Tube Epithelium and Serous Tubal Intraepithelial Carcinoma.
Abdelhamed ZA; Ryan TA; Fuller M; Coulson-Gilmer C; Abdelmottaleb DI; Wang TL; Kaun JC; Wang P; Hutson R; Wilkinson N; Bell SM; Johnson CA
Int J Gynecol Cancer; 2018 Oct; 28(8):1535-1544. PubMed ID: 30095490
[TBL] [Abstract][Full Text] [Related]
9. [Morphological features of the fimbria of the fallopian tube in pelvic serous adenocarcinoma].
Guo DH; Pang SJ; Shen Y; Li Y
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):287-90. PubMed ID: 21575501
[TBL] [Abstract][Full Text] [Related]
10. Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer.
Nishida N; Murakami F; Higaki K
Pathol Int; 2016 Jun; 66(6):337-42. PubMed ID: 27250113
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of p-ERM, a marker of cell polarity, in benign and neoplastic oviductal epithelium.
Ning G; Bijron JG; Yuan J; Hirsch MS; McKeon FD; Nucci MR; Crum CP; Xian W
Int J Gynecol Pathol; 2013 Jul; 32(4):345-52. PubMed ID: 23722506
[TBL] [Abstract][Full Text] [Related]
12. [The morphological and immunohistochemical characteristics of changes in the fallopian tube mucosa in ovarian epithelial tumors].
Asaturova AV; Ezhova LS; Faizullina NM; Sannikova MV; Khabas GN
Arkh Patol; 2016; 78(2):3-9. PubMed ID: 27070769
[TBL] [Abstract][Full Text] [Related]
13. HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes.
Wei JJ; Wu J; Luan C; Yeldandi A; Lee P; Keh P; Liu J
Am J Surg Pathol; 2010 Jan; 34(1):18-26. PubMed ID: 19898227
[TBL] [Abstract][Full Text] [Related]
14. [New concept in serous adenocarcinoma of fallopian tube].
Guo DH; Pang SJ; Li J; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):490-3. PubMed ID: 22932467
[No Abstract] [Full Text] [Related]
15. Immunohistochemical and molecular pattern of p53 in epithelial ovarian cancers negative for germline BRCA1/2 variants.
Ronchi S; Facchi S; Di Lauro E; Libera L; Carnevali IW; Zefiro F; Alexandrova E; Rizzo F; Sessa F; Tibiletti MG
Pathol Res Pract; 2024 Mar; 255():155183. PubMed ID: 38364651
[TBL] [Abstract][Full Text] [Related]
16. Fallopian tube abnormalities in uterine serous carcinoma.
Steenbeek MP; Bulten J; Snijders MPLM; Lombaers M; Hendriks J; van den Brand M; Kraayenbrink AA; Massuger LFAG; Sweegers S; de Hullu JA; Pijnenborg JMA; Küsters-Vandevelde HVN; Reijnen C
Gynecol Oncol; 2020 Aug; 158(2):339-346. PubMed ID: 32409160
[TBL] [Abstract][Full Text] [Related]
17. IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis.
Wang Y; Li L; Wang Y; Yuan Z; Zhang W; Hatch KD; Zheng W
J Exp Clin Cancer Res; 2014 Jul; 33(1):60. PubMed ID: 25038792
[TBL] [Abstract][Full Text] [Related]
18. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube.
Chen EY; Mehra K; Mehrad M; Ning G; Miron A; Mutter GL; Monte N; Quade BJ; McKeon FD; Yassin Y; Xian W; Crum CP
J Pathol; 2010 Sep; 222(1):110-6. PubMed ID: 20597068
[TBL] [Abstract][Full Text] [Related]
19. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.
Karst AM; Levanon K; Duraisamy S; Liu JF; Hirsch MS; Hecht JL; Drapkin R
Gynecol Oncol; 2011 Oct; 123(1):5-12. PubMed ID: 21683992
[TBL] [Abstract][Full Text] [Related]
20. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube.
Xian W; Miron A; Roh M; Semmel DR; Yassin Y; Garber J; Oliva E; Goodman A; Mehra K; Berkowitz RS; Crum CP; Quade BJ
J Pathol; 2010 Jan; 220(1):17-23. PubMed ID: 19834951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
